Rosetta Genomics Stock Current Valuation
Valuation analysis of Rosetta Genomics helps investors to measure Rosetta Genomics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Rosetta Genomics Company Current Valuation Analysis
Rosetta Genomics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Rosetta Genomics Current Valuation | 2.09 M |
Most of Rosetta Genomics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rosetta Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Rosetta Genomics has a Current Valuation of 2.09 M. This is 99.99% lower than that of the sector and 99.61% lower than that of the Current Valuation industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
Rosetta Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rosetta Genomics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rosetta Genomics could also be used in its relative valuation, which is a method of valuing Rosetta Genomics by comparing valuation metrics of similar companies.Rosetta Genomics is currently under evaluation in current valuation category among related companies.
Rosetta Fundamentals
| Return On Equity | -137.95 | |||
| Return On Asset | -60.19 | |||
| Operating Margin | (370.55) % | |||
| Current Valuation | 2.09 M | |||
| Shares Outstanding | 5.93 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 14.42 % | |||
| Number Of Shares Shorted | 310.26 K | |||
| Price To Earning | (0.09) X | |||
| Price To Book | 1.01 X | |||
| Price To Sales | 0.72 X | |||
| Revenue | 2.86 M | |||
| Gross Profit | 498 K | |||
| EBITDA | (10.35 M) | |||
| Net Income | (9.48 M) | |||
| Cash And Equivalents | 1.32 M | |||
| Cash Per Share | 0.51 X | |||
| Total Debt | 2.45 M | |||
| Debt To Equity | 222.80 % | |||
| Current Ratio | 2.09 X | |||
| Book Value Per Share | 0.43 X | |||
| Cash Flow From Operations | (11.68 M) | |||
| Short Ratio | 1.54 X | |||
| Earnings Per Share | (6.41) X | |||
| Price To Earnings To Growth | (0.01) X | |||
| Number Of Employees | 86 | |||
| Beta | 0.64 | |||
| Market Capitalization | 2.07 M | |||
| Total Asset | 22.42 M | |||
| Retained Earnings | (140.27 M) | |||
| Working Capital | 16.57 M | |||
| Current Asset | 19.37 M | |||
| Current Liabilities | 2.8 M | |||
| Z Score | -8.4 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Rosetta Genomics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Rosetta Genomics' short interest history, or implied volatility extrapolated from Rosetta Genomics options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Rosetta Stock
If you are still planning to invest in Rosetta Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rosetta Genomics' history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |